PCM
GPCR icon

Peregrine Capital Management’s Structure Therapeutics GPCR Stock Holding History

Peregrine Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.95M Sell
92,229
-4,888
-5% -$216K 0.16% 205
2026
Q1 		$4.68M Buy
97,117
+12,793
+15% +$876K 0.17% 195
2025
Q4 		$5.86M Buy
+84,324
New +$3.44M 0.18% 158

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Peregrine Capital Management's GPCR Position: Q2 2026 in Review

Peregrine Capital Management reduced its Structure Therapeutics (GPCR) stake by 5% in Q2 2026, selling an estimated $216K and leaving 92,229 shares worth $4.95M. The position accounts for 0.16% of the portfolio, ranked #205.

Peregrine Capital Management first reported a position in GPCR in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.86M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Peregrine Capital Management held 92,229 shares of Structure Therapeutics worth $4.95M as of Q2 2026.
  • Peregrine Capital Management sold 4,888 Structure Therapeutics shares in Q2 2026, an estimated $216K.
  • Structure Therapeutics made up 0.16% of Peregrine Capital Management's portfolio in Q2 2026, its #205 holding.
  • Peregrine Capital Management first reported a position in Structure Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Peregrine Capital Management's Structure Therapeutics position peaked at $5.86M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.